FR901228 in Treating Patients With Recurrent High-Grade Gliomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

depsipeptide

Given IV

Trial Locations (8)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

University of Pittsburgh, Pittsburgh

20814

National Cancer Institute Neuro-Oncology Branch, Bethesda

53792

University of Wisconsin, Madison

77030

MD Anderson Cancer Center, Houston

90095

University of California Los Angeles, Los Angeles

94143

University of California San Francisco, San Francisco

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00085540 - FR901228 in Treating Patients With Recurrent High-Grade Gliomas | Biotech Hunter | Biotech Hunter